Advertisement

Advertisement

AACR Annual Meeting 2022

Solid Tumors
Genomics/Genetics

PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors

The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Dru...

issues in oncology
genomics/genetics

Nickolas Papadopoulos, PhD, on Multicancer Early Detection: Opportunities and Challenges

Nickolas Papadopoulos, PhD, of the Sidney Kimmel Comprehensive Cancer Center, discusses early detection as the key to reducing cancer mortality and the lack of tests for many malignancies. Liquid biop...

Prostate Cancer

Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer

The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large ge...

pancreatic cancer
genomics/genetics

Christine A. Iacobuzio-Donahue, MD, PhD, on Pancreatic Cancer: Novel Insights Into Genetics and Evolution

Christine A. Iacobuzio-Donahue, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses her research on the evolutionary features of advanced stage pancreatic cancers and the insights that may b...

Lymphoma
Immunotherapy

Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma

Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretrea...

Lung Cancer

2-Year Follow-up Shows Durable Responses With Sotorasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer

Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-u...

issues in oncology
genomics/genetics

Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research

Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in prec...

issues in oncology
genomics/genetics

Priscilla K. Brastianos, MD, on CNS Metastases: Understanding Their Evolution and the Clinical Implications

Priscilla K. Brastianos, MD, of Harvard Medical School and Massachusetts General Hospital, talks about her efforts to better understand how brain metastases evolve genomically and to test such agents ...

gynecologic cancers
breast cancer
pancreatic cancer
prostate cancer
genomics/genetics

Timothy A. Yap, MBBS, PhD, on Ovarian, Breast, Pancreatic, and Prostate Cancers With Genetic Mutations: A First-in-Human Trial of AZD5305

Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the PETRA study, a first-in-class, first-in-human trial of the next-generation PARP1-selective i...

issues in oncology

Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic

Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential o...

solid tumors

Timothy A. Yap, MBBS, PhD, on Advanced Solid Tumors With DNA Damage Response Defects: Early Data on Elimusertib

Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from a phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin

Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The c...

issues in oncology
immunotherapy

Lillian L. Siu, MD, on Looking Toward the Future of Clinical Research and Clinical Trials

Lillian L. Siu, MD, of Canada’s Princess Margaret Cancer Centre, discusses biomarker-driven precision cancer medicine, the optimal sequencing of immunotherapy (IO) with standard treatments in curative...

issues in oncology

Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment

Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers...

Breast Cancer

Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports

Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR...

genomics/genetics
issues in oncology

Cheryl L. Willman, MD, on Cancer Genomic Sequencing in Tribal Nations of the American Southwest

Cheryl L. Willman, MD, of the Mayo Clinic Comprehensive Cancer Center, discusses the profound cancer health disparities among Native Americans, exacerbated by low rates of screening and limited access...

gastroesophageal cancer

Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy

Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab ...

lung cancer

David A. Barbie, MD, on Mesothelioma: Activating the STING Pathway May Promote Antitumor Immunity

David A. Barbie, MD, of Dana-Farber Cancer Institute, discusses his laboratory’s studies, showing that malignant pleural mesothelioma, an inflamed cancer type with marginal response to immune checkpoi...

lung cancer
genomics/genetics

Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease

Jia Luo, MD, of Dana-Farber Cancer Institute, discusses the emerging class of cancer therapies for allele-specific KRAS inhibitors and the importance of their distinct clinical, genomic, and immunolog...

issues in oncology

Gautam Mehta, MD, on Precision Oncology: An Overview of the Accelerated Approval Program

Gautam Mehta, MD, of the U.S. Food and Drug Administration, discusses how accelerated approval of potentially life-saving cancer therapies has been applied in precision oncology. Although “fast-tracki...

lung cancer
immunotherapy

Nicolas Girard, MD, PhD, on NSCLC: New Data on Event-Free Survival With Nivolumab Plus Platinum-Doublet Chemotherapy

Nicolas Girard, MD, PhD, of the Institut Curie, discusses findings from the phase III CheckMate 816 trial, which is the first study with an immunotherapy-based combination to demonstrate improved even...

Solid Tumors

Therapies Targeting DNA Damage Response Show Antitumor Activity

Results from two early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—the ATR inhibitor elimusertib and the PARP inhibitor AZD5305—are safe and clini...

Breast Cancer
Colorectal Cancer
Immunotherapy

Researchers Seek to Expand Immunotherapy Options for Patients With Advanced Breast and Colorectal Cancers

Two presentations given at the American Association for Cancer Research (AACR) Annual Meeting 2022 focused on promising strategies for making breakthrough immunotherapies work for more patients. Both ...

Symptom Management

AI Model May Help Predict Adverse Events From New Drug Combinations

Preliminary data from an artificial intelligence (AI) model could potentially predict side effects resulting from new combination therapies, according to results presented by Küçükosmanoğlu et al at t...

Genomics/Genetics

New Bioinformatics Platform Optimizes Selection of Combination Cancer Therapies

Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occ...

Leukemia

Patients With ALL and Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T-Cell Therapy

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted chimeric antigen receptor (CAR) T-cell therapy had gene regulation signatures that could potential...

Skin Cancer

Ipilimumab Plus Nivolumab Improves Progression-Free Survival in Advanced Melanoma

Patients with advanced melanoma whose cancer does not respond to treatment with PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug, a CTLA-4 inhibitor such as the...

Hematologic Malignancies
COVID-19

Novel COVID-19 Vaccine May Provide Protection for Patients With B-Cell Deficiencies

CoVac-1, a new vaccine against SARS–CoV-2, induced T-cell immune responses in 93% of patients with B-cell deficiencies, including many patients with leukemia and lymphoma, according to results present...

Lung Cancer
Immunotherapy

In the Neoadjuvant Setting, Combination Immunotherapy With Durvalumab Is More Effective Than Durvalumab Alone for Early-Stage NSCLC

Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (...

Immunotherapy

New CAR T-Cell Therapy for Solid Tumors Was Safe and Showed Early Efficacy

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid...

Prostate Cancer

Accounting for Genetic Factors That Cause Normal Variations in PSA Levels May Improve the Accuracy of Prostate Cancer Detection

The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting for genetic factors that cause changes in PSA levels not associated with cancer, according...

Leukemia

Study Examines Disparities in Relapse Among Pediatric Patients With ALL

According to a large multiethnic study presented by Sok et al at the American Association for Cancer Research (AACR) Annual Meeting 2022, Latinx children with acute lymphoblastic leukemia (ALL) and me...

colorectal cancer
covid-19

Maria Elena Martinez, PhD, MPH, on Colorectal Cancer Screening in Underserved Populations: COVID, Silver Linings, and Challenges Ahead

Maria Elena Martinez, PhD, MPH, of the University of California, San Diego Moores Cancer Center, provides an overview of the key components of the Accelerating Colorectal Cancer Screening and Follow-u...

issues in oncology

Electra D. Paskett, PhD, on Social Stresses and Cancer Treatment: An Expert Perspective

Electra D. Paskett, PhD, of The Ohio State University, discusses various factors that may contribute to cancer such as socioeconomic status, discrimination, violence, and access to health care. When c...

breast cancer

Meenakshi Anurag, PhD, on Breast Cancer: New Data on Combining Anastrozole and Fulvestrant

Meenakshi Anurag, PhD, of Baylor College of Medicine, discusses results from the ALTERNATE trial, which showed the combination of anastrozole plus fulvestrant was superior to either drug alone in inhi...

skin cancer
immunotherapy

Iván Márquez-Rodas, MD, PhD, on Advanced Melanoma: Efficacy of Intratumoral BO-112 With Systemic Pembrolizumab

Iván Márquez-Rodas, MD, PhD, of Spain’s Hospital General Universitario Gregorio Marañón, discusses final results of the phase II SPOTLIGHT203 study of systemic pembrolizumab in combination with intrat...

immunotherapy

Silvia C. Formenti, MD, on Adapting Radiation Therapy to Immune Checkpoint Blockade

Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses research on the best way to integrate radiotherapy with immune modifiers, which might require changes in standard radiation oncology practi...

lung cancer
immunotherapy

Tina Cascone, MD, PhD, on NSCLC: New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy

Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the findings of the phase II NeoCOAST study, which showed that combination immunotherapy with the anti–PD-L1 mono...

genomics/genetics

Patricia M. LoRusso, DO, on Targeting KRAS: Clinical Successes and Challenges

Patricia M. LoRusso, DO, of the Yale University School of Medicine, discusses how patients may benefit in the coming decade from discoveries about agents that target KRAS, and how important the approv...

Lymphoma

Novel Approach Using Off-the-Shelf Preactivated NK Cells Shows Efficacy in CD-30 Positive Lymphoma

Natural killer (NK) cells derived from donated umbilical cord blood and activated with a novel bispecific antibody known as AFM13 (which targets CD16A and CD30) were shown to be effective in patients ...

Lung Cancer

Sotorasib Achieves Durable Responses in KRAS G12C–Mutated Lung Cancer

Sotorasib, the first KRAS G12C inhibitor approved for the treatment of KRAS G12C–mutated non–small cell lung cancer (NSCLC), continues to demonstrate meaningful and durable efficacy at 2-year follow-u...

issues in oncology

Klaus Pantel, MD, on Liquid Biopsy Research: Opportunities and Challenges

Klaus Pantel, MD, of the University Medical Center Hamburg-Eppendorf, discusses liquid biopsy technologies and biomarkers, with a focus on circulating tumor cells and circulating tumor DNA; clinical a...

skin cancer
immunotherapy

Ari M. VanderWalde, MD, MPH, MBioeth, on Melanoma: New Data on Ipilimumab and Nivolumab

Ari M. VanderWalde, MD, MPH, MBioeth, of The West Clinic, discusses results from the S1616 trial involving patients with metastatic or unresectable melanoma who had primary resistance to PD-1 or PD-L1...

issues in oncology

Vivek Subbiah, MD, on Designing Clinical Trials for Precision Oncology

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, talks about innovative design of clinical studies that may help demonstrate clinical benefit in precision medicine and advance ...

Global Cancer Care
COVID-19

Pediatric Patients With Cancer in Lower- and Middle-Income Countries Faced a Significantly Higher Mortality Risk During the COVID-19 Pandemic

During the first 9 months of the COVID-19 pandemic, patients with pediatric cancer from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countrie...

Breast Cancer

Recurrent Noninvasive Breast Tumors May Not Always Be Related to the Primary Lesion

More than 10% of cases of recurrent ductal carcinoma in situ (DCIS) of the breast were de novo tumors that occurred independently of the primary lesion and had distinct genetic alterations, according ...

Pancreatic Cancer

An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records

An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified a subset of individuals with a 25-fold risk of developing pancreatic...

gynecologic cancers

Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin

Benoit You, MD, PhD, of the Lyon University Hospital (France), discusses phase I/II safety and efficacy results from the ENDOLA trial that combined olaparib with metronomic cyclophosphamide and metfor...

solid tumors

Josh Neman, PhD, on Brain Metastasis: A Neuroscience Perspective

Josh Neman, PhD, of the Keck School of Medicine, University of Southern California, discusses the distribution of brain metastasis to preferential brain regions that vary according to cancer subtype, ...

lung cancer

Alana L. Welm, PhD, on Metastatic Outgrowth in the Lungs: Identifying a New Immune-Mediated Pathway

Alana L. Welm, PhD, of the University of Utah Huntsman Cancer Institute, discusses her findings of a new pathway that regulates the antitumor immune response during metastatic outgrowth. Interfering w...

Advertisement

Advertisement



Advertisement